Nektar Therapeutics
Market cap $1.23B 34.2M shares (10-Q, Nov 6, 2026) × $35.91 close Nov 17, 2026
Most recent annual filing: 2026-03-13
- amlitelimab Sanofi filing2H 2026amlitelimab Sanofi filing, 2H 2026, notable
- Rezpegaldesleukin trial start2H 2026Rezpegaldesleukin trial start, 2H 2026, routine
- undisclosed Treg indication trial start2H 2026undisclosed Treg indication trial start, 2H 2026, routine
- Rezpegaldesleukin AD readout1Q 2027Rezpegaldesleukin AD readout, 1Q 2027, major
- Rezpegaldesleukin T1D Ph2 interim2027Rezpegaldesleukin T1D Ph2 interim, 2027, notable
- AA registrational Phase 3 Ph3Early 2027AA registrational Phase 3 Ph3, Early 2027, routine
- Rezpegaldesleukin ZENITH Ph3 toplinemid-2028Rezpegaldesleukin ZENITH Ph3 topline, mid-2028, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (11 active programs)
rezpegaldesleukin
NKTR-358NKTR-0165
- Undisclosed indication
NKTR-0166
- Undisclosed indication
NKTR-255
NKTR-422
- Undisclosed indication
rezpegaldesleukin
NKTR-288
- Undisclosed indication
Capital (as filed)
- Cash
- $34.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $580M Sep 30, 2026
- Long-term investments
- $339M Sep 30, 2026
- Operating cash flow
- −$71.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $953M cash, runway third quarter of 2028 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-14 UPDATE: Nektar Therapeutics (NKTR) - The Runway Is Back, and One Pivotal Changed Shape 🔒 Paid
- 2026-11-13 UPDATE: Nektar Therapeutics (NKTR) - The Premium Is Almost Gone 🔒 Paid
- 2026-10-02 UPDATE: Nektar Therapeutics (NKTR) - Eight Patients Carry the Durability Story ★ Distilled Pro
- 2026-09-25 UPDATE: Nektar Therapeutics (NKTR) - The Docket Delivers $90M 🔒 Paid
- 2026-09-11 UPDATE: Nektar Therapeutics (NKTR) - The Quiet Period Is the Catalyst 🔒 Paid
- 2026-08-14 UPDATE: Nektar Therapeutics (NKTR) - The Runway Just Got a Deadline
- 2026-07-24 UPDATE: Nektar Therapeutics (NKTR) - The Phase 3 Clock Starts (and Amlitelimab’s Head Start Widens) 🔒 Paid
- 2026-06-06 Nektar Therapeutics (NKTR) — Scientific Deep Dive for Rezpegaldesleukin and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Nektar Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-06 Watch Nektar Therapeutics (NKTR) — Scientific Deep Dive for Rezpegaldesleukin and Pipeline Products First-in-class Treg biology and fortress balance sheet are real, but middling efficacy, a post-hoc-rescued AA primary, and a competitor a full cycle ahead in AD don't justify chasing a 570% move.
- 2026-07-24 Watch UPDATE: Nektar Therapeutics (NKTR) - The Phase 3 Clock Starts (and Amlitelimab's Head Start Widens) Phase 3 initiated on schedule but mid-2028 topline widens amlitelimab's commercial head start; stock at ~$69 prices M&A optionality after a 570%+21% run.
- 2026-08-14 Watch UPDATE: Nektar Therapeutics (NKTR) - The Runway Just Got a Deadline Q3-2028 runway guidance converts the cash cushion into a countdown that clears the mid-2028 ZENITH topline by only one quarter, and the AA registrational trial is now dated for early 2027.
- 2026-09-11 Watch UPDATE: Nektar Therapeutics (NKTR) - The Quiet Period Is the Catalyst The quiet-period 8-K signals the REZOLVE-AA 24-week off-treatment readout is weeks away, creating an asymmetric binary where a soft durability result does real damage to the AA thesis.
- 2026-09-25 Watch UPDATE: Nektar Therapeutics (NKTR) - The Docket Delivers $90M Jury awarded $90M non-dilutive cash against Lilly but it remains a contested receivable; stock near the February offering price with the AA durability binary still ahead.
- 2026-10-02 Watch UPDATE: Nektar Therapeutics (NKTR) - Eight Patients Carry the Durability Story AA off-treatment durability points the right way in 5/8 one-year responders but is built on n=8 with a weaker 36-week cohort; valuation near cash-plus-modest-pipeline level but Q1-2027 AD off-treatment data is the better entry trigger.
- 2026-11-13 Watch UPDATE: Nektar Therapeutics (NKTR) - The Premium Is Almost Gone Rezpeg's value above cash has compressed to ~$0.3B, meeting the price condition for revisiting, but the data condition (Q1 2027 AD off-treatment read) has not yet been met; a small starter position may be reasonable for patient investors.
- 2026-11-14 Watch UPDATE: Nektar Therapeutics (NKTR) - The Runway Is Back, and One Pivotal Changed Shape Runway into Q3 2028 reaffirmed and burn partly explained by prepayments, but ZENITH AD-2 redesign as a TCS-combination trial removes naïve monotherapy replication; a small starter position remains reasonable ahead of Q1 2027 durability data.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
““We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational Phase 3 study in alopecia areata in early 2027.”
matched to Rezpegaldesleukin (AD) · readout other
-
-
-
““We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational Phase 3 study in alopecia areata in early 2027.”
matched to Rezpegaldesleukin (AD) · readout other / matched to ZENITH AD · Phase 3 topline / BLA
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (33)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 20268-KCurrent report: Reg FD disclosure→ BD updateThe Q3 10-Q quietly buries a material change: ZENITH AD-2 has been redesigned from a monotherapy trial into a combination study with topical corticosteroids — a protocol shift that narrows what that pivotal will prove on its own, while the 8-K finally puts in writing that cash clears the summer 2028 ZENITH readout.
- Nov 13, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseNektar Therapeutics Announces Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS."→ BD updateQ3 burn accelerates to ~$70M — the highest quarter yet — as legal costs spike and the ZENITH machine ramps; the stock now trades at barely $0.3B above cash, within range of the revisit level I named in October, while ZENITH AA pulled forward to December.
- Nov 11, 2026ReleaseNektar Therapeutics to Participate in Two Investor Conferences in November
- Oct 27, 2026ReleaseNektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
- Oct 1, 2026Release/UPDATE -- Nektar Therapeutics/→ BD updateSummary on the 8-K
- Oct 1, 2026ReleaseNew Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026→ BD updateSummary on the 8-K
- Oct 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE ISSUED BY NEKTAR THERAPEUTICS ON OCTOBER 1, 2026, FURNISHED HEREWI→ BD updateThe REZOLVE-AA 24-week off-treatment data landed at EADV this morning — 63% of responders maintained 80%+ scalp coverage six months after stopping rezpeg — but the stock dropped -17.6% to $46.99, because "63% of 8 patients" is the small-print asterisk that changes everything about how to read the headline.BD extracted 1 program update from this document → NKTR pipeline
- Sep 30, 2026ReleaseNew Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in PatientsBD extracted 1 program update from this document → NKTR pipeline
- Sep 28, 2026ReleaseNektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026BD extracted 1 program update from this document → NKTR pipeline
- Sep 25, 20268-KCurrent report: other events→ BD updateNektar won $90M from Lilly at trial — yet the stock is down 19% today. The verdict closes one tracked catalyst but the market's reaction suggests investors are reading the quiet-period data timing, not the litigation win, as the real signal.
- Sep 8, 20268-KCurrent report: Reg FD disclosure
- Aug 25, 2026ReleaseNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisBD extracted 1 program update from this document → NKTR pipeline
- Aug 14, 202610-QQuarterly report
- Aug 13, 2026ReleaseNektar Therapeutics Announces Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → NKTR pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS."
- Jul 28, 2026ReleaseNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
- Jul 21, 2026ReleaseNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisBD extracted 1 program update from this document → NKTR pipeline
- Jun 5, 20268-KCurrent report: shareholder vote
- May 8, 20268-KCurrent report: material agreement, officer / director change
- May 8, 2026424B5Prospectus supplement (offering)
- May 8, 202610-QQuarterly report
- May 7, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS."
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent report: material agreement, other events · EX-99.1
- Apr 23, 2026424B5Prospectus supplement (offering)
- Apr 20, 20268-KCurrent report: Reg FD disclosure
- Apr 20, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 20, 2026424B5Prospectus supplement (offering)
- Mar 13, 202610-KAnnual report
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2
14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 20, 2026S-8Employee plan registration
- Sep 28, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026S-8Employee plan registration
- Jul 31, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026SCHEDULE 13G/A13G amendment
- Apr 24, 2026ARSAnnual report to shareholders
- Apr 17, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 27, 2026SCHEDULE 13G/A13G amendment
- Mar 6, 2026SCHEDULE 13GPassive >5% holder (13G)